BUYINS.NET: Market Maker Surveillance Report. Top 6 Losing Stocks With Lowest Price Friction For March 11, 2009

Mar 12, 2009 (M2 PRESSWIRE via COMTEX) --
UTHR | Quote | Chart | News | PowerRating -- BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for March 11, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This "fair market making" requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3,635 companies with "abnormal" market making, 2,936 companies with positive Friction Factors and 2,450 companies with negative Friction Factors. Here is a list of the top 6 companies with the largest dollar loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. McKesson Corp. (NYSE: MCK | Quote | Chart | News | PowerRating), Chattem (NASDAQ: CHTT | Quote | Chart | News | PowerRating), United Therapeutics (NASDAQ: UTHR), Boston Beer Co. (NYSE: SAM | Quote | Chart | News | PowerRating), Myriad Genetics (NASDAQ: MYGN | Quote | Chart | News | PowerRating) and Amerisource Bergen Corp. (NYSE: ABC | Quote | Chart | News | PowerRating). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net.

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

MCK -$6.95 -16.58% 4,917,302 35.59% 5,012,668 36.28% -95,366 -137

CHTT -$4.73 -7.92% 644,940 47.47% 701,043 51.60% -56,103 -119

UTHR -$3.94 -6.24% 483,774 48.95% 494,762 50.06% -10,988 -28

SAM -$3.82 -17.25% 201,806 34.57% 232,073 39.75% -30,267 -79

MYGN -$3.22 -3.94% 341,064 43.55% 431,779 55.14% -90,715 -282

ABC -$3.03 -9.71% 2,365,219 36.41% 2,849,641 43.87% -484,422 -1,599

Click here to view chart: http://www.buyins.com/ff/fftopl3-11-09.jpg

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows MCK with a dollar loss Wednesday of -$6.95 and a Friction Factor of -137 shares. That means that it only took 137 more shares of selling than buying to move MCK lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

McKesson Corporation (NYSE: MCK), together with its subsidiaries, provides supply, information, and care management products and services for the healthcare industry. It operates in two segments, Distribution Solutions and Technology Solutions. The Distribution Solutions segment distributes ethical and proprietary drugs, medical-surgical supplies and equipment, and health and beauty care products in North America. It also provides specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, as well as pharmacy software, consulting, outsourcing, and other services. In addition, this segment, through its 49% interest in Nadro, S.A. de C.V., distributes pharmaceuticals in Mexico; and 39% interest in Parata Systems, LLC, sells automated pharmacy and supply management systems and services to retail and institutional outpatient pharmacies. The Technology Solutions segment delivers enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions; pharmacy automation for hospitals; and connectivity, outsourcing, and other services. It also offers InterQual, a clinical auditing, and compliance and medical management software, as well as care management programs. This segment serves hospitals, physicians, homecare providers, retail pharmacies, and payors in North America, the United Kingdom, other European countries, and the Asia Pacific region. McKesson Corporation was founded in 1833 and is based in San Francisco, California.

Chattem, Inc. (NASDAQ: CHTT), together with its subsidiaries, engages in the manufacture and marketing of over-the-counter (OTC) healthcare products, toiletries, and dietary supplements. The company markets its products under various brand names in categories, such as medicated skin care, topical pain care, oral care, internal OTC, medicated dandruff shampoos, dietary supplements, and other OTC and toiletry products. It sells medicated skin care products under the brands Gold Bond, Cortizone-10, and Balmex; topical pain care products under the Icy Hot, Aspercreme, Flexall, Capzasin, Sportscreme, and Arthritis Hot brand names; oral care products under the brands ACT, Herpecin-L, and Benzodent; and internal OTC products under the Pamprin, Premsyn PMS, Unisom, and Kaopectate brand names. The company also offers medicated dandruff shampoos under the brands Selsun Blue, Selsun Salon, and Selsun Natural; dietary supplement products under the Dexatrim, Garlique, Melatonex, New Phase, and Omnigest EZ brand names; and other OTC and toiletry products under the brands Bullfrog, Sun-In, UltraSwim, and Mudd. Chattem markets its products to mass merchandisers, and drug and food retailers in the United States, Canada, Peru, and Europe. The company was founded in 1879 and is headquartered in Chattanooga, Tennessee.

United Therapeutics Corporation (NASDAQ: UTHR), a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases. It offers products primarily in three therapeutic areas, including cardiovascular, cancer, and infectious diseases. The company's products include Remodulin, inhaled and oral Treprostinil, Beraprost-MR, and inhaled Treprostinil with AERx essence for the treatment of pulmonary arterial hypertension. It also offers CardioPAL SAVI wireless cardiac event monitors, which are in phase II trials; and CardioPAL SAVI and Decipher cardiac monitors for cardiac arrhythmias and ischemic heart disease. In addition, the company is developing 3F8 MAb that is in phase II trial for Neuroblastoma; oral Treprostinil, which is in phase II trial for peripheral vascular disease; Miglustat for Hepatitis C that is in phase I trial; inhaled Treprostinil, which is in phase I trial for Idiopathic pulmonary fibrosis; 8H9 MAb for Metastatic brain cancer that is in phase I trial; Glycobiology antiviral agents for Hepatitis C and other infectious diseases, which are in preclinical stage. Further, United Therapeutics provides telemedicine services to detect cardiac arrhythmias and ischemic heart diseases. It has operations primarily in the United States, Europe, and Asia. The company has strategic alliance with Medtronic MiniMed for the use of pager-sized continuous microinfusion pump for delivery of Remodulin subcutaneously; and a license, development, and commercialization agreement with Aradigm Corporation to manufacture, develop, and commercialize its AERx Essence device, a pulmonary drug delivery system. United Therapeutics was founded in 1996 and is headquartered in Silver Spring, Maryland.

The Boston Beer Company, Inc. (NYSE: SAM | Quote | Chart | News | PowerRating) produces and sells low alcohol beverages primarily in the United States, Canada, Europe, Israel, the Caribbean, the Pacific Rim, and Mexico. The company markets approximately 20 beers under the 'Samuel Adams' or the 'Sam Adams' brand names; 7 flavored malt beverage products under the 'Twisted Tea' brand name; and 1 hard cider product under the 'HardCore Cider' brand name. It also produces malt beverages and hard cider products under contract for third parties. The company sells its products to a network of wholesale distributors, who then sell to retailers, such as pubs, restaurants, grocery chains, package stores, stadiums, and other retail outlets. The Boston Beer Company was founded in 1984 and is based in Boston, Massachusetts.

Myriad Genetics, Inc. (NASDAQ: MYGN), a healthcare company, engages in the development and marketing of molecular diagnostic and therapeutic products. Its products include BRACAnalys for assessing a woman's risk for breast and ovarian cancer; COLARIS molecular for assessing a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP, a molecular diagnostic product for colon cancer that detects mutations in the APC and MYH genes; MELARIS, which analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma, a skin cancer; and THERAGUIDE 5-FU that analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of 5-FU toxicity and guides physician dosing decisions. The company markets its products through its own sales force in the United States and through marketing collaborations internationally. It is also developing Azixa, a phase II drug candidate for solid primary and metastatic brain tumors; Vivecon, a phase I preclinical drug candidate for AIDS; MPC-2130, a phase I drug for hematologic cancers; MPC-3100, a late stage preclinical drug for the treatment of cancer; and MPC-0920, a phase I drug for thrombosis. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

AmerisourceBergen Corporation (NYSE: ABC), a pharmaceutical services company, offers drug distribution and related services to healthcare providers and pharmaceutical manufacturers in the United States, the United Kingdom, and Canada. It distributes brand name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers, such as acute care hospitals and health systems, independent and chain retail pharmacies, mail order facilities, physicians, medical clinics, and long-term care and other alternate site pharmacies. The company also provides pharmacy management, staffing and other consulting services, scalable automated pharmacy dispensing equipment, medication and supply dispensing cabinets, and supply management software to retail and institutional healthcare providers. In addition, it offers distribution and other services to physicians, who specialize in various disease states; distributes vaccines, injectibles, and plasma and other blood products; and provides commercialization services, third party logistics, group purchasing services, and other services for biotech and other pharmaceutical manufacturers, as well as reimbursement consulting, data analytics, practice management, and physician education. Further, AmerisourceBergen delivers unit dose, punch card, unit-of-use, and compliance and other packaging solutions to institutional and retail healthcare providers; and offers contract packaging and clinical trial materials services for pharmaceutical manufacturers. It serves customers through a network of distribution and service centers, and packaging facilities. The company was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,500,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

CONTACT: Thomas Ronk, CEO, BUYINS.NET
Tel: +1 800 715 9999
e-mail: Tom@buyins.net
WWW: http://www.buyins.net

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Mckesson Corp (MCK) MCK. Mckesson Corp (MCK) has Short Term PowerRatings at TradingMarkets. Details on Mckesson Corp (MCK) Short Term PowerRatings is available at This Link.

For full details on Myriad Genetics Inc (MYGN) MYGN. Myriad Genetics Inc (MYGN) has Short Term PowerRatings at TradingMarkets. Details on Myriad Genetics Inc (MYGN) Short Term PowerRatings is available at This Link.

For full details on Chattem Inc (CHTT) CHTT. Chattem Inc (CHTT) has Short Term PowerRatings at TradingMarkets. Details on Chattem Inc (CHTT) Short Term PowerRatings is available at This Link.

For full details on AmerisourceBergen Corp (ABC) ABC. AmerisourceBergen Corp (ABC) has Short Term PowerRatings at TradingMarkets. Details on AmerisourceBergen Corp (ABC) Short Term PowerRatings is available at This Link.

For full details on Boston Beer Co (SAM) SAM. Boston Beer Co (SAM) has Short Term PowerRatings at TradingMarkets. Details on Boston Beer Co (SAM) Short Term PowerRatings is available at This Link.

For full details on United Therapeutics Corp (UTHR) UTHR. United Therapeutics Corp (UTHR) has Short Term PowerRatings at TradingMarkets. Details on United Therapeutics Corp (UTHR) Short Term PowerRatings is available at This Link.